ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

Corti, Davide; Zhao, Jincun; Pedotti, Mattia; Simonelli, Luca; Agnihothram, Sudhakar; Fett, Craig; Fernandez-Rodriguez, Blanca; Foglierini, Mathilde; Agatic, Gloria; Vanzetta, Fabrizia; Gopal, Robin; Langrish, Christopher J.; Barrettg, Nicholas A.; Sallusto, Federica; Baric, Ralph S.; Varani, Luca; Zambon, Maria; Perlman, Stanley; Lanzavecchia, Antonio*广州医学院; 1; 5
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA2015-8-18DOI: 10.1073/pnas.1510199112
159被引11阅读
引用收藏
分享

摘要

Middle East Respiratory Syndrome (MERS) is a highly lethal pulmonary infection caused by a previously unidentified coronavirus (CoV), likely transmitted to humans by infected camels. There is no licensed vaccine or antiviral for MERS, therefore newprophylactic and therapeutic strategies to combat human infections are needed. In this study, we describe, for the first time, to our knowledge, the isolation of a potent MERS-CoV-neutralizing antibody from memory B cells of an infected individual. The antibody, named LCA60, binds to a novel site on the spike protein and potently neutralizes infection of multiple MERS-CoV isolates by interfering with the binding to the cellular receptor CD26. Importantly, using mice transduced with adenovirus expressing human CD26 and infected with MERS-CoV, we show that LCA60 can effectively protect in both prophylactic and postexposure settings. This antibody can be used for prophylaxis, for postexposure prophylaxis of individuals at risk, or for the treatment of human cases of MERS-CoV infection. The fact that it took only 4 mo from the initial screening of B cells derived from a convalescent patient for the development of a stable chinese hamster ovary (CHO) cell line producing neutralizing antibodies at more than 5 g/L provides an example of a rapid pathway toward the generation of effective antiviral therapies against emerging viruses.

学科与关键词

关键词
MERS-CoVneutralizing antibodyserotherapyemerging viruses
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
发表日期
2015-08-18
卷期
第 112 卷, 第 33 期
页码
10473-10478
DOI
10.1073/pnas.1510199112
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q1
成果收录
SCIE
资助标注
National Institute of Allergy and Infectious Diseases (NIAID) [AI085524, AI110700]; NIH [RO1 AI091322, PO1 AI060699]; Public Health England; Swiss National Science Foundation [147662, 138518]; Swiss Vaccine Research Institute; Helmut Horten Foundation; NIAID [HHSN272201000013I]

作者

  • C

    Corti, Davide (第一作者)

  • Z

    Zhao, Jincun

    1 · guangzhou med univ

查看全部 19 位作者收起作者
  • P

    Pedotti, Mattia

  • S

    Simonelli, Luca

  • A

    Agnihothram, Sudhakar

  • F

    Fett, Craig

  • F

    Fernandez-Rodriguez, Blanca

  • F

    Foglierini, Mathilde

  • A

    Agatic, Gloria

  • V

    Vanzetta, Fabrizia

  • G

    Gopal, Robin

    5

  • L

    Langrish, Christopher J.

    1

  • B

    Barrettg, Nicholas A.

    2 · 1

  • S

    Sallusto, Federica

  • B

    Baric, Ralph S.

  • V

    Varani, Luca

  • Z

    Zambon, Maria

    5

  • P

    Perlman, Stanley

  • L

    Lanzavecchia, Antonio (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417